NF Trinity Capital’s Denali Therapeutics DNLI Stock Holding History

NF Trinity Capital’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-112,273	Closed	-$2.44M	–	51
2018 Q3	$2.44M	Hold	112,273	–	–	0.32%	46
2018 Q2	$1.71M	Sell	112,273 -3,253	-3%	-$61.3K	0.23%	52
2018 Q1	$2.27M	Buy	115,526 +15,526	+16%	+$319K	0.31%	50
2017 Q4	$1.56M	Buy	+100,000	New	+$1.8M	0.2%	49

Other funds holding DNLI

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

NF Trinity Capital's DNLI Position: Q4 2018 in Review

NF Trinity Capital sold out of Denali Therapeutics (DNLI) in Q4 2018, closing a stake of 112,273 shares — an estimated $2.44M sold.

NF Trinity Capital first reported a position in DNLI in Q4 2017 and held it in 4 quarters. The position peaked at $2.44M in Q3 2018. 90 funds tracked by Wall St. Rank hold DNLI as of Q4 2018.

NF Trinity Capital reported no remaining Denali Therapeutics position as of Q4 2018 after selling out during the quarter.
NF Trinity Capital sold 112,273 Denali Therapeutics shares in Q4 2018, an estimated $2.44M.
NF Trinity Capital first reported a position in Denali Therapeutics in Q4 2017 and held it in 4 quarters.
NF Trinity Capital's Denali Therapeutics position peaked at $2.44M in Q3 2018.
90 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2018.

Based on NF Trinity Capital's 13F filing for Q4 2018, filed 31 Jan 2019.